NAPWA

A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART)

Improving antiretroviral treatment (ART) initiation for people living with HIV in Australia: a realistic and viable approach? Sub-study 3: interviewing people diagnosed with HIV currently not on ART.
Tags: Understanding HIV treatments, living with HIV, starting treatments

Rosuvastatin versus Protease Inhibitor switching for Hypercholesterolaemia in people with HIV.
Tags: cholesterol, clinical trials, lipid disorders, treatment side effects

Opposites Attract

A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults

This is a Randomized, Double Blind Study to look at the Safety and Efficacy of a novel Integrase Inhibitor (II) Dolutegravir at a dosage of 50mg taken once a day compared with Raltegravir 400mg taken twice a day. Both 'arms' are Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy Over 96 Weeks among people with HIV who have not previously taken Antiretroviral Therapy.

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults
Tags: heart disease

A Multicenter, Randomized, Double Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir +Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naïve HIV Infected Patients With Ccr5 Tropic HIV 1
Tags: maraviroc

Strategic Timing of AntiRetroviral Treatment (START)
Tags: starting treatments

A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes.
Tags: genital herpes